Rate My Professor Hassan Choucair

Choucair's research specializations lie in drug discovery, oncology, and cancer biology, particularly mechanisms involving endoplasmic reticulum stress, mitochondrial targeting, and apoptosis in triple-negative breast cancer cells such as MDA-MB-231. Notable publications include 'A novel arylurea fatty acid that targets the mitochondrion and depletes cardiolipin to promote killing of breast cancer cells' (Journal of Medicinal Chemistry, 2017); 'The aryl-ureido fatty acid CTU activates endoplasmic reticulum stress and PERK/NOXA-mediated apoptosis in tumor cells by a dual mitochondrial-targeting mechanism' (Cancer Letters, 2022); 'Aryl-urea fatty acids that activate the p38 MAP kinase and down-regulate multiple cyclins decrease the viability of MDA-MB-231 breast cancer cells' (European Journal of Pharmaceutical Sciences, 2019); 'The Novel Anticancer Aryl-Ureido Fatty Acid CTU Increases Reactive Oxygen Species Production That Impairs Mitochondrial Fusion Mechanisms and Promotes MDA-MB-231 Cell Death' (International Journal of Molecular Sciences, 2024); and 'The inositol-requiring enzyme 1 (IRE1) endoplasmic reticulum stress pathway promotes MDA-MB-231 cell survival and renewal in response to the aryl-ureido fatty acid CTU' (The International Journal of Biochemistry & Cell Biology, 2024), the latter affiliated with Notre Dame Australia. At the university, he received the Early Career Researcher Award (AUD $10,000, 2024) for 'Enhancing Anticancer Drug Development by Targeting Endoplasmic Reticulum Stress in Triple-Negative Breast Cancer' and the Scholarship of Teaching and Learning Seed Grant (AUD $5,000, 2024) for 'Transforming Health Science Learning with AI Chatbot Technology.' Additional honors include the Australian Government Research Training Program Scholarship (2016-2019, AUD $26,682 p.a.) and the Sydney Catalyst Professor Rob Sutherland Travel and Education Award (2019, AUD $2,000).